their biggest intraday drop since March 2020. The stock had gained 29% this year through Friday’s close, outperforming a 26% rise in the S&P 500. “This outcome is a real dagger” for AbbVie ...

AbbVie will not be pursued any further by the US government over allegations that it used 'sham' litigation to keep competition to its AndroGel testosterone replacement product off the market.

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

The advantage of SLT over eye drops occurred despite ongoing treatment ... Lind disclosed relationships with AbbVie, Heru, Nicox, and SpyGlass. Source Reference: Montesano G, et al "Six-year ...